Regulated Cell Death in Neurodegenerative Disorders
- 1st Edition - June 29, 2025
- Editors: Heba Mohamed Mansour, Aiman Saad El-Khatib
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 3 2 8 5 2 - 7
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 3 2 8 5 3 - 4
In the realm of neurodegeneration, the intricate balance between life and death within cells is a subject of profound importance and intrigue. Regulated Cell Death (RCD) has become… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteRegulated Cell Death in Neurodegenerative Disorders explores the discovery, features, and implications of RCD in the context of neurodegenerative diseases. Each chapter delves into different RCD mechanisms, such as apoptosis, necroptosis, ferroptosis, pyroptosis, and autophagy-mediated cell death, providing unique insights into cellular demise in different neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, Multiple sclerosis, Amyotrophic lateral sclerosis, and Huntington’s disease.
Regulated Cell Death in Neurodegenerative Disorders features 14 chapters written by renowned experts in this field. Explore the complex world of RCD, covering its origins, mechanisms, and impact on neurodegenerative diseases, providing valuable insights into treatment options and therapeutic targets. Discover the diverse aspects of RCD modalities, the importance of chaperones, kinases, growth factors, inflammaging, mitochondrial dynamics, oxidative stress, and targeted strategies to prevent cell death in neurodegenerative disorders. This book covers molecular, cellular, and pharmacological mechanisms in all chapters from an applied science perspective.
This book not only shares knowledge but also offers hope by presenting therapeutic strategies to modulate RCD for combating neurodegenerative diseases. It reflects the ongoing pursuit of understanding, innovative treatments, and unraveling the mysteries surrounding cellular death in neurodegenerative contexts.
- Provides a comprehensive overview of different types of RCD
- Dissects the crosstalk between different types of RCD
- Explores the relevance of RCD mechanisms to neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, Multiple sclerosis, Amyotrophic lateral sclerosis, and Huntington’s disease
- Examines several forms of regulated cell death, including apoptosis, necroptosis, ferroptosis, pyroptosis, and autophagy-mediated cell death
- Discusses the effect of Inflammaging and oxidative stress on different types of RCD
- Delves into the effect of chaperones, kinases, and growth factors on different RCD machinery
- Discusses the potential of targeted therapies aimed at interdicting cell death machineries
- Explores disease-modifying agents targeting RCD in neurodegenerative disorders
Chapter 2. Crosstalk Between Different Regulated Cell Death Mechanisms in Neurodegenerative Diseases
Chapter 3. Apoptosis in Neurodegenerative Disorders
Chapter 4. Necroptosis in Neurodegenerative Disorders
Chapter 5. Ferroptosis in Neurodegenerative Disorders
Chapter 6. Pyroptosis in Neurodegenerative Disorders
Chapter 7. Autophagy-Mediated Cell Death: Mechanisms and Implications in Neurodegenerative Disorders
Chapter 8. Potential targets for regulating cell death in neurodegenerative diseases
Chapter 9. Neuroprotective Role of Molecular Chaperones: Regulating Cell Survival and Death
Chapter 10. Navigating the Kinases Landscape: Impact on Regulated Cell Death mechanisms in Neurodegenerative disorders
Chapter 11: Growth Factors and regulated cell death in neurodegenerative disorders
Chapter 12. Regulated Cell Death and Inflammaging in Neurodegenerative Disorders
Chapter 13. Role of Oxidative Stress and Mitochondrial Dysfunction in Neurodegenerative Disorders
Chapter 14. Therapeutic Approaches Targeting Regulated Cell Death in Neurodegenerative Diseases: Current Understanding and Recent Advances in Combating Neuronal Loss
- No. of pages: 600
- Language: English
- Edition: 1
- Published: June 29, 2025
- Imprint: Academic Press
- Paperback ISBN: 9780443328527
- eBook ISBN: 9780443328534
HM
Heba Mohamed Mansour
Heba Mohamed Mansour, Ph.D. is currently the Manager of the Innovative Products' Technical Evaluation Unit at the Central Administration of Biological, Innovative Products, and Clinical Studies (Bio-Inn) at the Egyptian Drug Authority (EDA). She is a topic leader in the ICH working group (EWG S13), specializing in non-clinical safety assessments of oligonucleotide-based therapeutics (ONTs). Heba received a PhD degree in pharmacology and toxicology from the Faculty of Pharmacy, Cairo University in 2024. Her expertise encompasses a profound understanding of diverse cell death modalities in neurodegeneration and the exploration of potential drug repositioning strategies involving anti-cancer kinase inhibitors for neurodegenerative disorders. Her contributions extend to numerous research articles, prestigious international journal publications, book chapters, books, and comprehensive review articles, solidifying her interest in the field.
AE
Aiman Saad El-Khatib
Aiman Saad El-Khatib, Ph.D. is currently the Vice President of the Egyptian Drug Authority. He is a Professor of Pharmacology and Toxicology in the Faculty of Pharmacy, Cairo University since May 2002. He held several leadership positions in Cairo University including Vice President for Graduate Studies and Research Affairs, Dean of Faculty of Pharmacy, Vice Dean for Education and Students Affairs as well as Vice Dean for Community Service and Environment Development. Additionally, he held the post of Assistant Minister of Health and Population for Pharmaceutical Affairs. His primary research area of interest is the investigation of the pharmacological properties of various drugs, including natural products on the gastrointestinal tract, cardiovascular and central nervous systems. He published numerous articles in international journals. His awards include Cairo University Scientific Research Fosterage in the field of Theoretical and Applied Biological Sciences in 2004 and, Silver and Gold Medal of Merit from Egyptian Syndicate of Pharmacists in 2004 and 2005.